Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer - Takeaways - MDSpire

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • By

  • Meghna S. Trivedi

  • Joseph M. Unger

  • N. Lynn Henry

  • Amy K. Darke

  • Daniel L. Hertz

  • Thomas H. Brannagan

  • Stephanie J. Reyes

  • Bryan P. Schneider

  • William J. Irvin

  • Amanda R. Hathaway

  • Amy C. Vander Woude

  • Vinay K. Gudena

  • Paula Cabrera-Galeana

  • Mary Orsted

  • Michael LeBlanc

  • Michael J. Fisch

  • Dawn L. Hershman

  • April 10, 2026

  • 0 min

Share

  • 1

    Taxane-induced peripheral neuropathy (TIPN) affects up to 70% of patients receiving taxane chemotherapy for early-stage cancer.

  • 2

    The SWOG S1714 study aims to develop a predictive model for assessing TIPN risk in patients undergoing taxane-based treatment.

  • 3

    Risk factors for TIPN include demographic characteristics, lifestyle factors, comorbid conditions, and treatment-related variables.

  • 4

    The study enrolled participants with nonmetastatic cancer receiving paclitaxel or docetaxel, with assessments conducted over three years.

  • 5

    Statistical analysis will validate the TIPN risk prediction model, aiming for a significant difference in TIPN rates between high-risk and low-risk groups.

Original Source(s)

Predictive Model for Assessing the Risk of Taxane-Related Peripheral Neuropathy in Patients with Early-Stage Cancer

  • by Meghna S. Trivedi, Joseph M. Unger, N. Lynn Henry, Amy K. Darke, Daniel L. Hertz, Thomas H. Brannagan, Stephanie J. Reyes, Bryan P. Schneider, William J. Irvin, Amanda R. Hathaway, Amy C. Vander Woude, Vinay K. Gudena, Paula Cabrera-Galeana, Mary Orsted, Michael LeBlanc, Michael J. Fisch, Dawn L. Hershman

  • April 10, 2026

Related Content

Roswell Park at ASCO 2026: GLP-1s and Aggressive Breast Cancer, CAR T in Older Adults, AI-Informed Benchmarking

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago

  • by

  • May 25, 2026

  • 9 min
Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

Acupuncture for post-chemoradiotherapy complications in lung cancer with bone metastasis: a case report and literature review